Trial aims to stop dangerous transplant complication with fewer drugs
NCT ID NCT06252870
Summary
This study is testing a new way to prevent graft-versus-host disease (GVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant for blood cancer. Researchers want to see if a short, intense course of two drugs (cyclophosphamide and methotrexate) given right after the transplant can work as well as the standard longer-term medications, potentially allowing patients to stop preventive drugs much sooner. The trial will enroll 82 adults with blood cancers who are receiving a transplant from a matched donor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Angers
RECRUITINGAngers, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Brest
RECRUITINGBrest, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Nantes
RECRUITINGNantes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.